Intrauterine stroke from a sword on the face - A rare diagnosis and its long-term sequelae [0.03%]
面部中剑导致的宫内脑卒中的罕见病例及其长期后遗症
Josh Kumar,Sahil Agrawal,Neelam Pushker
Josh Kumar
Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead [0.03%]
抗血管内皮生长因子治疗后段眼病：进展、挑战与未来方向
Chitaranjan Mishra,Nabatika Mohanty,Somy Purohit et al.
Chitaranjan Mishra et al.
The emergence of anti-vascular endothelial growth factor (anti-VEGF) therapy has marked a paradigm shift in the treatment of retinal and choroidal vascular diseases. Following the identification of VEGF as a central mediator of pathological...
Current role of aflibercept in retinopathy of prematurity - A review [0.03%]
阿柏西普在早产儿视网膜病变治疗中的作用初探-综述文章
Devesh Kumawat,Nawazish Shaikh,Parijat Chandra
Devesh Kumawat
The introduction of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has transformed the management of severe retinopathy of prematurity (ROP) in the zone I/zone II posterior region and aggressive ROP by enabling rapid di...
Anti-vascular endothelial growth factors in retinal and choroidal diseases - Present landscape [0.03%]
抗血管内皮生长因子治疗视网膜和脉络膜疾病之现况与展望
Naresh B Kannan,Muthukrishnan Vallinayagam,Konduru Rishitha et al.
Naresh B Kannan et al.
Anti-vascular endothelial growth factors (anti-VEGFs) are agents that block the activity of specific bio-active molecules responsible for the growth of abnormal blood vessels. The advent of anti-VEGF therapy has revolutionized the treatment...
Non-intravitreal anti-vascular endothelial growth factor delivery for ocular neovascular diseases: Current status and future directions [0.03%]
非静脉内血管内皮生长因子传递治疗眼新生血管性疾病：现状与未来方向
Shrinivas M Joshi,Giriraj Vibhute,Shailesh M Rao et al.
Shrinivas M Joshi et al.
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has fundamentally transformed the management of retinal and choroidal neovascular diseases. Despite its proven efficacy, long-term reliance on repeated intravitreal injecti...
The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema [0.03%]
人工智能在糖尿病性黄斑水肿治疗和患者选择中的作用的演变
Dhanashree Ratra,Ramachandran Rajalakshmi,M Suchetha et al.
Dhanashree Ratra et al.
Anti-vascular endothelial growth factor (anti-VEGF) therapy is the mainstay of management for diabetic macular edema (DME), but marked variability in response, high injection frequency, and cumulative treatment burden highlight the need for...
Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases [0.03%]
抗血管内皮生长因子玻璃体内注射治疗视网膜疾病的应用拓展
Shalini Singh,Urvashi Kala,Arjun Bamel et al.
Shalini Singh et al.
Vascular endothelial growth factor (VEGF) plays a central role in the pathogenesis of retinal and choroidal neovascularization, as well as macular edema (ME), in retinal disorders such as diabetic retinopathy, retinal vein occlusion (RVO), ...
Anti-vascular endothelial growth factor therapy in clinical practice: Real-world scenarios, limitations, and outcomes [0.03%]
临床实践中的抗血管内皮生长因子治疗：真实世界的案例、局限性及结局
Deepa Sharma,Twinkle Gupta
Deepa Sharma
This narrative review examines the "efficacy-effectiveness gap" in anti-vascular endothelial growth factor (anti-VEGF) therapy by comparing outcomes from randomized controlled trials (RCTs) with global and Indian real-world evidence (RWE) i...
Optimizing the invisible costs of anti-VEGF: The road to regularity [0.03%]
降低抗VEGF隐形成本的道路——通向规律治疗之路
Surbhi Agrawal
Surbhi Agrawal
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed outcomes in retinal disease, but its benefits depend on early initiation and sustained regular treatment. In India, poor adherence is often attributed ...
Lalit Verma,Shweta Singh,Obuli Ramachandran
Lalit Verma
Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of retinal vascular diseases over the past two decades. Beginning with the foundational identification of VEGF as the principal driver of ocular neov...